Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), announces the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. (“Life Molecular”), a subsidiary of Life Healthcare Group Holdings Ltd (“Life Healthcare”). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. Through the acquisition of Life Molecular, Lantheus gains Neuraceq® (florbetaben F18 injection), a globally1 approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s disease.
Read the full article: Lantheus Completes Acquisition of Life Molecular Imaging //
Source: https://www.globenewswire.com/news-release/2025/07/22/3119287/0/en/Lantheus-Completes-Acquisition-of-Life-Molecular-Imaging-and-Appoints-Dr-Ludger-Dinkelborg-as-Head-of-R-D.html